文献速递系统性红斑狼疮

系统性红斑狼疮限制口服糖皮质激素使用与预防损伤且不恶化长期疾病控制:一项观察性研究

Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-03-07

该观察性研究比较了自身免疫病单元(ADU)协议化治疗(羟氯喹普遍使用、口服泼尼松≤30 mg/d且维持≤5 mg/d、甲泼尼龙冲击和/或早期免疫抑制剂)与其他内科(IM)医生常规治疗对SLE患者损伤累积的影响。共纳入ADU组74例和IM组213例,随访≥5年。ADU组任何损伤累积更少(P=0.007),糖皮质激素相关损伤(调整HR 0.23 [95%CI 0.07-0.80])、心血管疾病损伤(调整HR 0.28 [95%CI 0.08-0.95])和无分类损伤(调整HR 0.58 [95%CI 0.3-1.1])更少,而SLE相关损伤两组相似(调整HR 0.84 [95%CI 0.40-1.75]),SLEDAI评分下降程度相似(P=0.4)。

要点

  • ADU协议限制口服泼尼松剂量并联合羟氯喹、甲泼尼龙冲击和早期免疫抑制剂。
  • ADU组任何损伤累积更少(P=0.007),糖皮质激素相关和心血管损伤显著减少。
  • 两组SLEDAI评分下降相似(P=0.4),SLE相关损伤累积无差异。

核心结论

  • 限制口服泼尼松剂量并通过联合不同治疗实现,可减少糖皮质激素相关损伤并改善心血管预后,且不增加SLE所致损伤。

研究设计与样本

  • 观察性研究,根据负责医生将患者分为ADU组(74例)和IM组(213例),随访≥5年。
  • ADU组遵循协议:普遍处方羟氯喹、口服泼尼松最大剂量≤30 mg/d且维持≤5 mg/d、使用甲泼尼龙冲击和/或早期免疫抑制剂。

主要发现

  • ADU组患者接受泼尼松更晚且剂量更低,更多使用甲泼尼龙冲击、早期免疫抑制剂和羟氯喹(所有比较P<0.05)。
  • ADU组任何损伤累积的可能性更低(P=0.007)。
  • ADU组糖皮质激素相关损伤调整HR 0.23(95%CI 0.07-0.80),心血管疾病损伤调整HR 0.28(95%CI 0.08-0.95),无分类损伤调整HR 0.58(95%CI 0.3-1.1)。
  • 两组SLE相关损伤累积相似(调整HR 0.84 [95%CI 0.40-1.75]),SLEDAI评分下降程度相似(P=0.4)。

关键数值与推荐

  • ADU协议:口服泼尼松最大剂量≤30 mg/d,维持剂量≤5 mg/d。
  • ADU组任何损伤累积更少(P=0.007);糖皮质激素相关损伤调整HR 0.23(95%CI 0.07-0.80);心血管疾病损伤调整HR 0.28(95%CI 0.08-0.95);无分类损伤调整HR 0.58(95%CI 0.3-1.1);SLE相关损伤调整HR 0.84(95%CI 0.40-1.75)。

临床怎么用

  • 在SLE长期管理中,可考虑限制口服泼尼松剂量(最大≤30 mg/d、维持≤5 mg/d),并联合羟氯喹、甲泼尼龙冲击和早期免疫抑制剂以控制疾病活动。
  • 该策略可能减少糖皮质激素相关损伤和心血管疾病损伤,且不增加SLE相关损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the influence of 2 different treatment strategies on general and specific damage accrual in patients with systemic lupus erythematosus (SLE). METHODS: Two cohorts were identified according to the responsible physicians: patients treated at the autoimmune diseases unit (ADU), and patients treated by other members of the internal medicine (IM) department. Members of the ADU worked with a protocol including the universal prescription of hydroxychloroquine (HCQ), the use of maximum oral prednisone dosages ≤30 mg/day and maintenance therapy with ≤5 mg/day, by using methylprednisolone pulses and/or early immunosuppressive (IS) drugs. We analyzed the influence of these 2 treatment strategies on damage accrual, both general and domain specific, attributed to glucocorticoids, cardiovascular (CV) disease, SLE, and unclassified, since the diagnosis of disease in patients with a followup ≥5 years. RESULTS: A total of 74 patients were included in the ADU group and 213 in the IM group. They were comparable for most demographic and lupus-related variables. ADU patients received prednisone later and at lower doses, more methylprednisolone pulses, earlier IS drugs and more HCQ (P < 0.05 for all comparisons). The Systemic Lupus Erythematosus Disease Activity Index score decreased similarly in both cohorts (P = 0.4). Patients in the ADU group were less likely to accrue any damage (P = 0.007). They accrued less glucocorticoid-related (adjusted hazard ratio [HR] 0.23 [95% confidence interval (95% CI) 0.07-0.80]), CV disease (adjusted HR 0.28 [95% CI 0.08-0.95]), and unclassified damage (adjusted HR 0.58 [95% CI 0.3-1.1]). Both groups accrued similar SLE-related damage (adjusted HR 0.84 [95% CI 0.40-1.75]). CONCLUSION: The use of reduced oral prednisone doses, which was possible by combining different therapies, reduced glucocorticoid-related damage and improved CV prognosis without increasing damage caused by SLE.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. Arthritis Care Res (Hoboken). 2018. PMID: 28704598. doi:10.1002/acr.23322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。